RT Journal Article
SR Electronic
T1 Diagnosis and Tracking of Past SARS-CoV-2 Infection in a Large Study of Vo’, Italy Through T-Cell Receptor Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228023
DO 10.1101/2020.11.09.20228023
A1 Gittelman, Rachel M.
A1 Lavezzo, Enrico
A1 Snyder, Thomas M.
A1 Zahid, H. Jabran
A1 Elyanow, Rebecca
A1 Dalai, Sudeb
A1 Kirsch, Ilan
A1 Baldo, Lance
A1 Manuto, Laura
A1 Franchin, Elisa
A1 Vecchio, Claudia Del
A1 Simeoni, Fabio
A1 Bordini, Jessica
A1 Lorè, Nicola I.
A1 Lazarevic, Dejan
A1 Cirillo, Daniela M.
A1 Ghia, Paolo
A1 Toppo, Stefano
A1 Carlson, Jonathan M.
A1 Robins, Harlan S.
A1 Tonon, Giovanni
A1 Crisanti, Andrea
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228023.abstract
AB Measuring the adaptive immune response after SARS-CoV-2 infection may improve our understanding of COVID-19 exposure and potential future protection or immunity. We analyzed T-cell and antibody signatures in a large population study of over 2,200 individuals from the municipality of Vo’, Italy, including 70 PCR-confirmed SARS-CoV-2 cases (24 asymptomatic, 37 symptomatic, 9 hospitalized). Blood samples taken 60 days after PCR diagnosis demonstrated 97% (68/70) of the latter subjects had a positive T-cell test result, higher than an antibody serology assay (77%; 54/70 of subjects) performed on the same samples. The depth and breadth of the T-cell response was associated with disease severity, with symptomatic and hospitalized COVID-19 cases having significantly higher response than asymptomatic cases. In contrast, antibody levels at this convalescent time point were less informative as they did not correlate with disease severity. 45 additional suspected infections were identified based on T-cell response from the 2,220 subjects without confirmatory PCR tests. Among these, notably, subjects who reported symptoms or had household exposure to a PCR-confirmed infection demonstrated a higher T-cell test positive rate. Taken together, these results establish that T cells are a sensitive, reliable and persistent measure of past SARS-CoV-2 infection.Competing Interest StatementRM Gittelman, TM Snyder, R Elyanow, S Dalai, I Kirsch, L Baldo have employment and equity ownership with Adaptive Biotechnologies. HS Robins has employment, equity ownership, patents, and royalties with Adaptive Biotechnologies. HJ Zahid and JM Carlson have employment and equity ownership with Microsoft.Funding StatementThis work was supported by the Veneto region and was jointly funded by the UK Medical Research Council (MRC; grant MR/R015600/1), the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, the Abdul Latif Jameel Foundation and is also part of the EDCTP2 programme supported by the European Union. Support was also provided by the Fondazione Umberto Veronesi, Misura Ricerca Covid 19, year 2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The first sampling of the Vo' population was conducted within the surveillance programme established by the Veneto region and did not require ethical approval; the remaining sampling was approved by the Ethics Committee for Clinical Research of the province of Padua. Study participation was by consent. For participants under 18 years of age, consent was provided by a parent or legal guardian.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data for this cohort (as described in Lavezzo 2020) is available at https://github.com/ncov-ic/SEIR_Covid_Vo. T-cell repertoire profiles are available as part of the ImmuneCODE data resource (Nolan 2020), and can be downloaded from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at https://clients.adaptivebiotech.com/pub/covid-2020. https://github.com/ncov-ic/SEIR_Covid_Vo https://clients.adaptivebiotech.com/pub/covid-2020